Cargando…

Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia

BACKGROUND: Acute myeloid leukemia (AML) escape from immunosurveillance by immunosuppression. CD200 and CD56 expression represented an independent prognostic factor in many hematological malignancies but its importance in AML patients remains to be identified. METHODS: CD200 and CD56 expression were...

Descripción completa

Detalles Bibliográficos
Autores principales: Aref, Salah, Abousamara, Nashwa, El-Helaly, Emann, Mabed, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437307/
https://www.ncbi.nlm.nih.gov/pubmed/32212802
http://dx.doi.org/10.31557/APJCP.2020.21.3.743
_version_ 1783572609969946624
author Aref, Salah
Abousamara, Nashwa
El-Helaly, Emann
Mabed, Mohamed
author_facet Aref, Salah
Abousamara, Nashwa
El-Helaly, Emann
Mabed, Mohamed
author_sort Aref, Salah
collection PubMed
description BACKGROUND: Acute myeloid leukemia (AML) escape from immunosurveillance by immunosuppression. CD200 and CD56 expression represented an independent prognostic factor in many hematological malignancies but its importance in AML patients remains to be identified. METHODS: CD200 and CD56 expression were assessed in the bone marrow blasts for Fifty-two (52) newly diagnosed AML by flowcytometry before start of therapy. RESULTS: CD200 (+) expression was reported in 28.8% of patients while 17.3% of patients showed CD56(+) expression. M4 FAB revealed high frequency of both CD200(+) and CD56(+) expression. The overall survival of CD200(+) patients was 19.2% compared to 35.3% in CD200(-) (P= 0.049). On the other hand, CD56(+) patients had the lowest complete remission rate (22.2% vs. 53.4%). In addition, CD56(+) population had significant bad influence on overall survival than those of CD56(- )population (11.1 % vs. 35.5 %, P= 0.047). CONCLUSIONS: CD200 and CD56 positive expression by myeloblasts at diagnosis denote poor prognostic indicator and correlated with poor cytogenetic findings. CD200 could be used as therapeutic target in AML.
format Online
Article
Text
id pubmed-7437307
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-74373072020-09-02 Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia Aref, Salah Abousamara, Nashwa El-Helaly, Emann Mabed, Mohamed Asian Pac J Cancer Prev Research Article BACKGROUND: Acute myeloid leukemia (AML) escape from immunosurveillance by immunosuppression. CD200 and CD56 expression represented an independent prognostic factor in many hematological malignancies but its importance in AML patients remains to be identified. METHODS: CD200 and CD56 expression were assessed in the bone marrow blasts for Fifty-two (52) newly diagnosed AML by flowcytometry before start of therapy. RESULTS: CD200 (+) expression was reported in 28.8% of patients while 17.3% of patients showed CD56(+) expression. M4 FAB revealed high frequency of both CD200(+) and CD56(+) expression. The overall survival of CD200(+) patients was 19.2% compared to 35.3% in CD200(-) (P= 0.049). On the other hand, CD56(+) patients had the lowest complete remission rate (22.2% vs. 53.4%). In addition, CD56(+) population had significant bad influence on overall survival than those of CD56(- )population (11.1 % vs. 35.5 %, P= 0.047). CONCLUSIONS: CD200 and CD56 positive expression by myeloblasts at diagnosis denote poor prognostic indicator and correlated with poor cytogenetic findings. CD200 could be used as therapeutic target in AML. West Asia Organization for Cancer Prevention 2020-03 /pmc/articles/PMC7437307/ /pubmed/32212802 http://dx.doi.org/10.31557/APJCP.2020.21.3.743 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Aref, Salah
Abousamara, Nashwa
El-Helaly, Emann
Mabed, Mohamed
Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia
title Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia
title_full Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia
title_fullStr Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia
title_full_unstemmed Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia
title_short Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia
title_sort clinical significance of cd200 and cd56 expression in patients with acute myeloid leukemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437307/
https://www.ncbi.nlm.nih.gov/pubmed/32212802
http://dx.doi.org/10.31557/APJCP.2020.21.3.743
work_keys_str_mv AT arefsalah clinicalsignificanceofcd200andcd56expressioninpatientswithacutemyeloidleukemia
AT abousamaranashwa clinicalsignificanceofcd200andcd56expressioninpatientswithacutemyeloidleukemia
AT elhelalyemann clinicalsignificanceofcd200andcd56expressioninpatientswithacutemyeloidleukemia
AT mabedmohamed clinicalsignificanceofcd200andcd56expressioninpatientswithacutemyeloidleukemia